



PD-L1 in Epithelial ovarian, Fallopian tube, or Primary peritoneal Carcinoma (EOC): Scoring for a Newly Established Indication

Join us at the USCAP 2026 Annual Meeting

Wednesday, March 25 | 12:00 pm - 1:00 pm
Seminar Room 2

Lunch provided

The clinical landscape for PD-L1 testing continues to evolve, with the establishment of a new indication in ovarian cancer introducing important diagnostic and interpretive considerations for practicing pathologists.

In this session, Dr. Marie Smithgall will review PD-L1 assessment in epithelial ovarian, fallopian tube, and primary peritoneal carcinomas, with a focused discussion on scoring criteria and interpretation aligned with the newly established indication. Using practical, case-based examples, the presentation will highlight how scoring principles are applied in routine practice and address common challenges encountered during evaluation.

Through practical examples and case based insights, attendees will gain guidance on applying scoring criteria, navigating complex or borderline cases, and understanding how expanded PD L1 indications are influencing pathology practice.

This program discusses FDA approved PD L1 indications as of the date of presentation. Please refer to current product labeling for complete intended use information.

© Agilent Technologies, Inc. 2026
Published in the USA, February, 2026
D0144193_1.00



Speaker: Dr. Marie Smithgall

Assistant Professor, Department of
Pathology and Cell Biology
Anatomic Pathology and Personalized
Genomic Medicine
Columbia University Irving Medical Center

Dr. Marie Smithgall is a surgical and molecular pathologist focusing on gynecologic pathology and molecular oncology testing. She earned her M.D. from Columbia University College of Physicians and Surgeons where she then completed her residency in anatomic and clinical pathology. She completed a fellowship in Gynecologic and Perinatal Pathology at Weill Cornell Medicine before returning to Columbia for a fellowship in Molecular Genetic Pathology. Her research interests include molecular mechanisms of gynecologic cancers, and she is passionate about medical student and resident pathology education.

Why attend

- Gain clarity on PD-L1 scoring requirements for a newly established ovarian cancer indication
- Review practical approaches to interpretation using real-world cases
- Identify common pitfalls and challenging scenarios in daily diagnostic practice
- Strengthen confidence in applying PD-L1 results to support clinical decision-making